Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous adipose derived mesenchymal stem cells - Hope Biosciences

Next Previous
Drug Profile

Autologous adipose derived mesenchymal stem cells - Hope Biosciences

Alternative Names: Autologous HB-adMSCs; HB adMSCs; HB-adMSC

Latest Information Update: 05 Nov 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hope Biosciences
  • Developer Hope Biosciences; University of Texas Health Science Center at Houston
  • Class Antineoplastics; Mesenchymal stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II COVID 2019 infections; Crohn's disease; Juvenile rheumatoid arthritis; Multiple sclerosis; Parkinson's disease; Traumatic brain injuries
  • Phase I/II Alzheimer's disease; Musculoskeletal pain; Rheumatoid arthritis
  • Clinical Phase Unknown Brain injuries
  • No development reported Cerebral palsy; Glioblastoma; Huntington's disease; Osteoarthritis; Prostate cancer; Spinal cord injuries; Stroke; Thrombotic thrombocytopenic purpura

Most Recent Events

  • 22 Oct 2026 Hope Biosciences Research Foundation completes a trial in Brain injuries (In adolescents, In adults, In the elderly) in USA (IV) (NCT07164482)
  • 23 Jun 2026 Efficacy and adverse events data from a phase-I/II trial in Traumatic brain injuries released by Hope Biosciences
  • 05 Jan 2026 Hope Biosciences withdrawn a phase II trial for Juvenile rheumatoid arthritis (In Children, In adolescents) in USA (Parenteral) (NCT06623240)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top